Cytomegalovirus Immune Globulin (CMV-Ig): An Old Drug with Fewer Tricks - Removal of Prophylactic CMV-Ig Administration in CMV Mismatched Lung Transplant Recipients
The routine use of cytomegalovirus immune globulin (CMV-Ig) to provide passive immunity to cytomegalovirus (CMV) in patients is not supported in published literature. International guidelines do not advocate for the use of CMV-Ig alone in thoracic transplant and provide only weak recommendations for its role in combination with antiviral therapy for prevention of CMV. The utilization of CMV-Ig incurs significant cost, and carries the potential for infusion related toxicities. Furthermore, in 2012, an international survey reported only 38 % of thoracic transplant centers utilized CMV-Ig as part of a universal prophylaxis protocol.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: B.J. Pierce, C. Pham, S. Varnado Balk, H. Huang Tags: (1300) Source Type: research
More News: Antiviral Therapy | Cardiology | Cytomegalovirus | Gammagard Liquid | Heart | Heart Transplant | Lung Transplant | Privigen | Toxicology | Transplant Surgery | Transplants